Thanks to the drug-delivery technology of biotech Alkermes (Nasdaq: ALKS - News), a 20-year-old drug is about to get a new lease on life. On the basis of a very successful phase 3 study, Alkermes has filed for approval from the Food and Drug Administration for its long-acting injectable formulation of Vivitrex (naltrexone) for the treatment of alcoholism.
